ONCOLOGY journal

The management of ocular malignancies has historically straddled a fine line between ophthalmology and systemic oncology, occasionally falling into institutional silos that fragment patient care. With the recent appointment of ocular oncologist Miguel A. Materin, MD, to lead the adult and pediatric ocular oncology programs at Northwell Health, the institution is positioning itself to dismantle these barriers.

The FDA has cleared an investigational new drug application (IND) for the next-generation oncolytic virus UGN-501 in the treatment of patients with non-muscle invasive bladder cancer (NMIBC), according to a news release from the developer, UroGen Pharma.1 Moreover, a phase 1 study is expected to begin in the fourth quarter of 2026, which will evaluate the safety, tolerability, and feasibility of intravesical UGN-501 among patients with NMIBC.

Inotuzumab ozogamicin (Besponsa) cleared measurable residual disease (MRD) in most adults with B-cell acute lymphoblastic leukemia (ALL) in morphologic remission, according to findings from a single-center phase 2 trial (NCT01371630) published in Blood Cancer Journal.¹ What were the efficacy results with inotuzumab ozogamicin?

The head and neck cancer treatment landscape continues to evolve with practice-changing data and promising early-phase developments.

Dr. Zeidner explores molecular response milestone management, distinguishing between immediate response assessment requiring dose adjustments or agent switching versus long-term treatment-free remission trajectory evaluation. Both strategies intertwine in clinical practice, with early response patterns influencing eventual treatment discontinuation eligibility and success rates.

Sivraj Muralikrishnan, MD Articles by Sivraj Muralikrishnan, MD Sivraj Muralikrishnan, MD, highlighted top head and neck cancer data from ASCO, including the KEYNOTE-689 trial and the novel mRNA degrader REM-422.

Background Metaplastic carcinoma (Mp) is estimated to account for < 1% of breast cancer diagnoses and is associated with poor outcomes due to chemoresistance. Most are phenotypically high-grade and triple negative, accounting for their aggressive clinical behavior. Studies examining pathologic complete response (pCR) rates with neoadjuvant chemotherapy for Mp breast cancer have varied, ranging from 2% to 23%.

ByJessica F. Moore,Victoria Tiedemann,Julia Rozenberg,I. Angeles,Kamaljeet Singh,Stephanie Ng,Ashley R. Stuckey,Micaela A. Weaver,Jennifer Gass,William M. Sikov, MD,David A. Edmonson In 21 patients with metaplastic breast cancer receiving neoadjuvant chemotherapy, 48% achieved pCR—higher than prior estimates—with all pCR patients alive and disease-free at follow-up, suggesting modern regimens including pembrolizumab may improve outcomes in this chemoresistant subtype.

20 On the Upswing: A Retrospective Cohort Study Evaluating Neoadjuvant Chemotherapy Response in Metaplastic Breast Cancer Patients ByJessica F. Moore,Victoria Tiedemann,Julia Rozenberg,I. Angeles,Kamaljeet Singh,Stephanie Ng,Ashley R. Stuckey,Micaela A. Weaver,Jennifer Gass,William M. Sikov, MD,David A.

Articles by Kamaljeet Singh 20 On the Upswing: A Retrospective Cohort Study Evaluating Neoadjuvant Chemotherapy Response in Metaplastic Breast Cancer Patients ByJessica F. Moore,Victoria Tiedemann,Julia Rozenberg,I. Angeles,Kamaljeet Singh,Stephanie Ng,Ashley R. Stuckey,Micaela A. Weaver,Jennifer Gass,William M. Sikov, MD,David A.